Is mirikizumab available in the country? What is the market situation?

Milikizumab (Mirikizumab) is not currently available in the Chinese market. Although the drug has been approved and put into use in multiple international markets, the drug registration process in China is still in progress. There is a growing demand in the Chinese market for innovative biologics drugs, especially for immune system-mediated diseases such as ulcerative colitis (UC) and Crohn's disease (CD). As China's attention in the field of immunotherapy drugs increases, the potential market prospects of militizumab are widely optimistic.

Milizumab is a monoclonal antibody developed by Eli Lilly (Eli Lilly). It mainly relieves inflammatory responses caused by immune system abnormalities by inhibiting the IL-23 signaling pathway. This mechanism has shown significant clinical efficacy, so militizumab is considered to have great therapeutic potential in the treatment of ulcerative colitis and Crohn's disease.

Currently, the drug approval process in the Chinese market usually takes a long time, especially for biologic drugs, which require strict clinical data evaluation and quality control. Whether Militizumab can enter the Chinese market will depend on the approval process and regulatory requirements of the China National Medical Products Administration (NMPA). As China's biopharmaceutical market gradually opens up, the launch of milizumab is expected to provide new treatment options for patients, especially when current treatment options are limited.

Although the pricing of Milizumab has not yet been determined in China, its success in the international market may provide a reference for future pricing. With the promotion of Lilai in the Chinese market and the progress of the approval process, militizumab is expected to become one of the important drugs in this field.

Keyword tags: Mirikizumab, Mirikizumab, Chinese market, Lilai, drug approval, ulcerative colitis, Crohn's disease, biologics

Reference materials:https://www.ema.europa.eu/en/medicines/human/EPAR/omvoh